// App-Quantinova.ai

e14008 : Anti-EGFRvIII TandAbs recruiting either T- or NK-cells as bispecific therapeutic antibody candidates for the treatment of EGFRvIII+ tumors.

Researchers

Presenter

  • Martin Treder

Principal Investigators

  • Jens-Peter Marschner

  • Kristina Ellwanger

  • Stefan Knackmuss

  • Michael Weichel

  • Thorsten Gantke

  • Uwe Reusch

  • Ivica Fucek

  • Narendiran Rajasekaran

  • Xing Zhao

  • Holbrook Edwin Kohrt

Medical Centers

  • Affimed, Heidelberg, Germany

  • Affimed, Heidelberg, Germany

  • Affimed, Heidelberg, GA, Ghana

  • Center for Clinical Sciences Research Stanford, Stanford, CA

  • Tissue Engineering and Stem Cells Research Center, Department of Immunology, Guiyang Medical University, Guiyang, China

Locations

  • Ghana

  • Germany

  • United States

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Cluster of Differentiation 2AP

  • Fc gamma RIIIa

Drug/Treatment

  • EGFRvIII

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved